{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:56:56Z","timestamp":1767373016955,"version":"3.48.0"},"reference-count":42,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University Medicine Essen Clinician Scientist Academy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Multikinase inhibitors (MKIs) have transformed treatment for advanced radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) and medullary thyroid cancer (MTC). However, limited insight exists into management differences between expert centers and multicenter registries or clinical studies. Moreover, MKI efficacy in poorly differentiated thyroid cancer (PDTC) is underreported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis included 154 patients with thyroid cancer (51 PDTC, 49 DTC, 54 MTC) treated with MKIs from 2011 to 2024 at the Essen Endocrine Tumor Center by a consistent specialist team. Clinical characteristics, tumor genetics, time to treatment, and treatment outcomes were assessed. Cox regression analyses identified prognostic survival factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In (P)DTC, lenvatinib showed higher objective response rate (ORR) (64% vs 18%) and longer median progression-free survival (PFS) (22.4 vs 6.7 months) than sorafenib, especially in PDTC (21.2 vs 3.5 months). Lenvatinib-treated patients without bone metastases had higher ORR (74% vs 53%), while higher age and liver metastases were associated with shorter PFS (HR, 2.12, P = .039; HR, 2.34, P = .031). In MTC, vandetanib demonstrated higher ORR (60% vs 18%) and longer PFS (26.1 vs 10.0 months) than cabozantinib. Vandetanib as first-line showed higher ORR (67% vs 25%) and RET mutations correlated with longer PFS (HR, 0.14, P = .045).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lenvatinib outperformed sorafenib, particularly in PDTC, suggesting the need for alternative treatments. In MTC, vandetanib was more effective than cabozantinib, supporting its use as first-line therapy. However, the choice of MKI was determined by the treating physician. Our data highlight MKI effectiveness under expert-center management compared to prior trials and real-world data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf286","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T05:35:05Z","timestamp":1747978505000},"page":"167-179","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9441-3046","authenticated-orcid":false,"given":"Yara Maria","family":"Machlah","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-4341","authenticated-orcid":false,"given":"Tim","family":"Brandenburg","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Muchalla","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Tiedje","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]},{"name":"Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer , New York, NY 10065 ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Theurer","sequence":"additional","affiliation":[{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]},{"name":"Institute of Pathology, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Weber","sequence":"additional","affiliation":[{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]},{"name":"Clinic for Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Weber","sequence":"additional","affiliation":[{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]},{"name":"Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Dralle","sequence":"additional","affiliation":[{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]},{"name":"Department of General, Visceral and Transplantation Surgery, Division of Endocrine Surgery, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0357-4192","authenticated-orcid":false,"given":"Dagmar","family":"F\u00fchrer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, University of Duisburg-Essen , 45147 Essen ,","place":["Germany"]},{"name":"Endocrine Tumor Center and ENETS Center at West German Cancer Center (WTZ), Member of ENDO-ERN and EURACAN , 45147 Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"issue":"1","key":"2025121807420846300_dgaf286-B1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"issue":"10","key":"2025121807420846300_dgaf286-B2","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1089\/thy.2015.0104","article-title":"Survival from differentiated thyroid cancer: what has age got to do with it?","volume":"25","author":"Ganly","year":"2015","journal-title":"Thyroid"},{"issue":"8","key":"2025121807420846300_dgaf286-B3","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025121807420846300_dgaf286-B4","doi-asserted-by":"crossref","first-page":"e220021","DOI":"10.1530\/ETJ-22-0021","article-title":"Poorly differentiated thyroid carcinoma: a clinician's perspective","volume":"11","author":"Tong","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"9","key":"2025121807420846300_dgaf286-B5","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman","year":"2006","journal-title":"Cancer"},{"issue":"9940","key":"2025121807420846300_dgaf286-B6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"2025121807420846300_dgaf286-B7","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"2025121807420846300_dgaf286-B8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"29","key":"2025121807420846300_dgaf286-B9","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"24","key":"2025121807420846300_dgaf286-B10","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1002\/cncr.30252","article-title":"Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer","volume":"122","author":"Sherman","year":"2016","journal-title":"Cancer"},{"volume-title":"Direct Healthcare Professional Communication (DHPC): Caprelsa (Vandetanib): Restriction of Indication","year":"2023","author":"European Medicines Agency","key":"2025121807420846300_dgaf286-B11"},{"issue":"8","key":"2025121807420846300_dgaf286-B12","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025121807420846300_dgaf286-B13","doi-asserted-by":"crossref","unstructured":"Machlah YM, Brandenburg T, Muchalla P, et al \u00a0Supplemental_Materials \u201cComprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center\u201d. Figshare. 2025. 10.6084\/m9.figshare.29130305.v1","DOI":"10.1210\/clinem\/dgaf286"},{"issue":"2","key":"2025121807420846300_dgaf286-B14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1530\/EJE-19-0763","article-title":"Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data","volume":"182","author":"Aydemirli","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025121807420846300_dgaf286-B15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.7150\/jca.22318","article-title":"Lenvatinib in advanced radioiodine-refractory thyroid cancer\u2014a retrospective analysis of the Swiss lenvatinib named patient program","volume":"9","author":"Balmelli","year":"2018","journal-title":"J Cancer"},{"issue":"1","key":"2025121807420846300_dgaf286-B16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/thy.2017.0205","article-title":"Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice","volume":"28","author":"Berdelou","year":"2018","journal-title":"Thyroid"},{"issue":"2","key":"2025121807420846300_dgaf286-B17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s12020-020-02477-0","article-title":"Lenvatinib as first-line treatment for advanced thyroid cancer: long progression-free survival","volume":"72","author":"De Leo","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"2025121807420846300_dgaf286-B18","doi-asserted-by":"crossref","first-page":"bvac048","DOI":"10.1210\/jendso\/bvac048","article-title":"Lenvatinib therapy for advanced thyroid cancer: real-life data on safety, efficacy, and some rare side effects","volume":"6","author":"Hamidi","year":"2022","journal-title":"J Endocr Soc"},{"issue":"1","key":"2025121807420846300_dgaf286-B19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12020-020-02290-9","article-title":"Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina","volume":"69","author":"Jerkovich","year":"2020","journal-title":"Endocrine"},{"key":"2025121807420846300_dgaf286-B20","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.2147\/CMAR.S326255","article-title":"Low dose of lenvatinib treatment for patients of radioiodine-refractory differentiated thyroid carcinoma\u2014a real-world experience","volume":"13","author":"Jiang","year":"2021","journal-title":"Cancer Manag Res"},{"issue":"12","key":"2025121807420846300_dgaf286-B21","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1089\/thy.2019.0022","article-title":"Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: a Korean multicenter retrospective study","volume":"29","author":"Lee","year":"2019","journal-title":"Thyroid"},{"key":"2025121807420846300_dgaf286-B22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejca.2019.05.031","article-title":"Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy","volume":"118","author":"Locati","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"2025121807420846300_dgaf286-B23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1089\/thy.2019.0221","article-title":"Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer: real-world experiences","volume":"30","author":"Masaki","year":"2020","journal-title":"Thyroid"},{"key":"2025121807420846300_dgaf286-B24","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.3332\/ecancer.2023.1500","article-title":"Real-world analysis of the use of lenvatinib in differentiated thyroid cancers","volume":"17","author":"Peelay","year":"2023","journal-title":"Ecancermedicalscience"},{"key":"2025121807420846300_dgaf286-B25","doi-asserted-by":"crossref","first-page":"8834148","DOI":"10.1155\/2020\/8834148","article-title":"Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer (RELEVANT): a retrospective multicentric analysis of clinical practice in Austria","volume":"2020","author":"Rendl","year":"2020","journal-title":"Int J Endocrinol"},{"issue":"2","key":"2025121807420846300_dgaf286-B26","doi-asserted-by":"crossref","first-page":"e230003","DOI":"10.1530\/ETJ-23-0003","article-title":"Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma","volume":"12","author":"Roque","year":"2023","journal-title":"Eur Thyroid J"},{"issue":"10","key":"2025121807420846300_dgaf286-B27","first-page":"1531","article-title":"Real-world efficacy and safety of multi-tyrosine kinase inhibitors in radioiodine refractory thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"issue":"2","key":"2025121807420846300_dgaf286-B28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12020-021-02634-z","article-title":"Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution","volume":"73","author":"Porcelli","year":"2021","journal-title":"Endocrine"},{"issue":"5","key":"2025121807420846300_dgaf286-B29","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1089\/thy.2019.0476","article-title":"Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival: a multicenter study in Korea","volume":"30","author":"Song","year":"2020","journal-title":"Thyroid"},{"issue":"1","key":"2025121807420846300_dgaf286-B30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1089\/thy.2022.0054","article-title":"Lenvatinib compared with sorafenib as a first-line treatment for radioactive iodine-refractory, progressive, differentiated thyroid carcinoma: real-world outcomes in a multicenter retrospective cohort study","volume":"33","author":"Kim","year":"2023","journal-title":"Thyroid"},{"issue":"2","key":"2025121807420846300_dgaf286-B31","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s12020-023-03638-7","article-title":"Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States","volume":"84","author":"Worden","year":"2024","journal-title":"Endocrine"},{"issue":"6","key":"2025121807420846300_dgaf286-B32","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1530\/ERC-18-0049","article-title":"Prolonged duration of response in lenvatinib responders with thyroid cancer","volume":"25","author":"Gianoukakis","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2025121807420846300_dgaf286-B33","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.21873\/anticanres.12691","article-title":"Efficacy and safety of sorafenib in a racially diverse patient population with advanced hepatocellular carcinoma","volume":"38","author":"Schmidt","year":"2018","journal-title":"Anticancer Res"},{"issue":"2","key":"2025121807420846300_dgaf286-B34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/jc.2005-1534","article-title":"Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning","volume":"91","author":"Robbins","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025121807420846300_dgaf286-B35","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3803\/EnM.2020.687","article-title":"Vandetanib for the management of advanced medullary thyroid cancer: a real-world multicenter experience","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"4","key":"2025121807420846300_dgaf286-B36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/thy.2014.0361","article-title":"Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort","volume":"25","author":"Chougnet","year":"2015","journal-title":"Thyroid"},{"issue":"4","key":"2025121807420846300_dgaf286-B37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1530\/EJE-13-0825","article-title":"Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network","volume":"170","author":"Massicotte","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025121807420846300_dgaf286-B38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1089\/thy.2020.0206","article-title":"Real-world efficacy and safety of cabozantinib and vandetanib in advanced medullary thyroid cancer","volume":"31","author":"Koehler","year":"2021","journal-title":"Thyroid"},{"issue":"24","key":"2025121807420846300_dgaf286-B39","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.19.02790","article-title":"Efficacy and safety of vandetanib in progressive and symptomatic medullary thyroid cancer: post hoc analysis from the ZETA trial","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025121807420846300_dgaf286-B40","first-page":"A266","article-title":"Cabozantinib therapy in medullary thyroid carcinoma patients outside a clinical trial","volume":"25","author":"Tiedje","year":"2015","journal-title":"Thyroid"},{"key":"2025121807420846300_dgaf286-B41","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2020.12.032","article-title":"Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer","volume":"147","author":"Tahara","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025121807420846300_dgaf286-B42","first-page":"PS3-29-08","article-title":"Efficacy of tyrosine-kinase-inhibition in thyroid cancer\u2014a retrospective, single-centre, real-world evaluation","volume":"92","author":"Lahner","year":"2023","journal-title":"Endocrine Abstracts"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf286\/63306417\/dgaf286.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/1\/167\/63306417\/dgaf286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/1\/167\/63306417\/dgaf286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T12:42:38Z","timestamp":1766061758000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/1\/167\/8142194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,23]]},"published-print":{"date-parts":[[2025,12,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf286","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"type":"print","value":"0021-972X"},{"type":"electronic","value":"1945-7197"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,5,23]]}}}